CURIS

Curis Lifesciences is actively transitioning from contract manufacturing and merchant exports to higher-margin own-brand marketing. This strategy aims to increase the own-brand contribution from the current 1% to 5-7% by March 2027, with a long-term target of 80% within 3-5 years. This shift, while capital-intensive and lengthy due to product registration processes, is expected to drive significant profitability improvements and reduce reliance on lower-margin business models.

The company reported a revenue of 2791.01 lakhs for September 2025, with a healthy EBITDA margin of 21.46% and PAT margin of 15.09%. Management highlighted a significant increase in EBITDA margin from 10.27% in FY23 to 24.38% in FY24, and 21.40% in FY25, attributing this to a better product mix and higher-margin exports. A target of 22% EBITDA margin is set for FY28, reflecting confidence in the ongoing strategic shift.

Curis is focusing on Nigeria for its initial own-brand marketing expansion, leveraging a partnership with Eurosun Pharmaceuticals, a local merchant exporter. This collaboration aims to expedite market entry and product registration, with the first 1-2 product registrations expected by March 2027. The company plans to establish its own offices and infrastructure in Nigeria to support this growth, utilizing Eurosun's market knowledge to mitigate entry risks.

The company confirmed that it does not require significant capital expenditure for capacity expansion, as existing manufacturing machines are sufficient to meet future demand. IPO proceeds are being utilized to enhance working capital, which was previously a constraint, enabling the company to increase its consumption capacity and smoothly manage the 90-100 day operating cycle for production and sales.

Management detailed the complex regulatory process for international market entry, involving extensive product development, stability testing, and country-specific registrations. A significant concern raised was the impact of geopolitical instability in Yemen, affecting 9 out of 12 export-ready products, which poses a risk to near-term export revenue. The company is actively managing these challenges while pursuing new market registrations.

Curis aims to mitigate competition in new markets by focusing on a few established brands and leveraging its existing product presence to build brand recognition. Following Nigeria, the company plans to explore market entry in Kenya and Ghana, with discussions for additional strategic partnerships ongoing to further expand its global footprint. The strategy is to capitalize on regions where multinational companies have less focus.